TLPH (Talphera) Days Payable : 0.00 (As of Mar. 2025)

View and export this data going back to 2011. Start your Free Trial

What is Talphera Days Payable?

Talphera's average Accounts Payable for the three months ended in Mar. 2025 was $0.50 Mil. Talphera's Cost of Goods Sold for the three months ended in Mar. 2025 was $0.00 Mil.

The historical rank and industry rank for Talphera's Days Payable or its related term are showing as below:

During the past 13 years, Talphera's highest Days Payable was 751.59. The lowest was 46.22. And the median was 147.62.

TLPH's Days Payable is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 87.915
* Ranked among companies with meaningful Days Payable only.

Talphera's Days Payable stayed the same from Mar. 2024 (0.00) to Mar. 2025 (0.00). stayed the same

Talphera Days Payable Historical Data

The historical data trend for Talphera's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Talphera Days Payable Chart

Talphera Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

Get a 7-Day Free Trial

134.85

236.23

751.59

Talphera Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Talphera's Days Payable

For the Drug Manufacturers - Specialty & Generic subindustry, Talphera's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Talphera's Days Payable Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Talphera's Days Payable distribution charts can be found below:

* The bar in red indicates where Talphera's Days Payable falls into.

Save Embed

;

Save Embed

;

Talphera Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Talphera's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (1.336	+	0.67)	/	2 )	/	0	*	365
=	1.003					/	0	*	365
=	N/A

Talphera's Days Payable for the quarter that ended in Mar. 2025 is calculated as:

	Days Payable (Q: Mar. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2024 )	+	Accounts Payable (Q: Mar. 2025 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2025 )	*	Days in Period
=	( (0.67	+	0.326)	/	2 )	/	0	*	365 / 4
=	0.498					/	0	*	365 / 4
=	N/A

Talphera Days Payable Related Terms

Thank you for viewing the detailed overview of Talphera's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Talphera Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Talphera Inc (NAS:TLPH) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

R5XA:Germany

Address

1850 Gateway Drive, Suite 175, San Mateo, CA, USA, 94404

Website

https://www.talphera.com

Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Executives

Vincent J. Angotti	director, officer: Chief Executive Officer	C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Raffi Asadorian	officer: Chief Financial Officer	C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Pamela P Palmer	director, officer: Chief Medical Officer	C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Jill Marie Broadfoot	director	3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Marina Bozilenko	director	C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Adrian Adams	director	C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19355
Mark G Edwards	director	ALLOS THERAPEUTICS, INC., 11080 CIRCLEPOINT ROAD, SUITE 200, WESTMINSTER CO 80020
Badri N Dasu	officer: Chief Engineering Officer	C/O ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Lawrence G Hamel	officer: Chief Development Officer	C/O ACELRX PHARMACEUTICALS INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Mark A Wan	director, 10 percent owner	C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Three Arch Associates Iii Lp	10 percent owner	C/O THREE ARCH PARTNERS, 3200 ALPINE ROAD, PORTOLA VALLEY CA 94028
Wilfred E Jaeger	10 percent owner	C/O THREE ARCH PARTNERS, 3200 ALPINE RD, PORTOLA VALLEY CA 94028
Three Arch Partners Iii Lp	10 percent owner
Three Arch Partners Iv Lp	10 percent owner
Three Arch Associates Iv Lp	10 percent owner	3200 ALPINE ROAD, PORTOLA VALLEY CA 94028